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Breast cancer is the most common type of cancer in women, and the most 
important and common cause of cancer-related deaths in women [1].  It is second only to 
lung cancer in the number of overall cancer-related deaths [2].  Breast cancer usually 
becomes refractory to chemotherapy within 2 to 5 years [3].  Surgery and radiation 
treatment are not options for some patients, especially those with metastatic disease [3].  
Some of these patients respond initially to modified chemotherapy, but, however, relapse 
after a short time.  The development of multi-drug resistance (MDR) in breast cancer 
remains a major obstacle in its treatment [4, 5, 6].  MDR is defined as a tumor’s 
resistance to an agent, and its cross-resistance to other agents structurally and 
functionally unrelated [6].  Cell lines (in vitro models) are important in the study of breast 
cancer and its resistance to chemotherapeutic agents, since experimental manipulations 
are more difficult to carry out on actual patients and often precluded by toxic side effects 
[6].  
Chemotherapeutic agents inhibit cell growth by affecting different parts of 
interphase and mitosis of cell division, thereby inducing apoptosis.  Apoptosis is defined 
as programmed cell death [1, 7].  
Human breast cancer MCF-7 cells are one of the models used to study multidrug 
resistance in breast cancer.  In order to learn more about the development of multi-drug 
resistance, investigation of cell lines at the proteomics level is necessary.  Proteomics is 
the identification and characterization of proteins expressed by an organism [8].  One 
must understand which proteins are present and which of those are differentially 
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expressed whether upregulated or downregulated in the drug resistant cell line.  Most of 
these proteins play important roles in the function and structure of the cell, but when 
either over -expressed or under-expressed can contribute to drug resistance.  It is 
important to construct a proteomic map of proteins from the drug susceptible cell line, 
which can be compared to the proteins from a drug resistant cell line, in order to explore 
the differentially expressed proteins in the two cell lines.  Therefore, comparative 
analysis of protein expression is an imperative aspect of the analysis of proteins 
contributing to diseases.  
In many of the mechanisms known to contribute to MDR, cells become resilient 
to drug-induced apoptosis [4].  Many proteins can contribute to this.  Some proteins 
inhibit apoptosis induced by cytotoxic drugs by preventing the release of cytochrome c 
into the cytosol [4].  Cytochrome c is released from the mitochondria to the cytosol in a 
very critical step in the activation of the apoptotic-signaling cascade [9].  
Caspase-3-protein is another protein involved in drug resistance.  Caspase-3-
protein is a cysteine protease [10].  Caspase activation is an important step in apoptosis 
and cytotoxic drug-induced apoptosis is mediated by caspase-3 [1, 11].  MCF-7 cells 
express a truncated isoform of the caspase-3 transcript, while the drug resistant cell lines 
express the full-length caspase-3 transcript [12].
 A major pathway involved in drug resistance is that involving growth factor 
receptor-mediated signal transduction [4, 13].  Although drug resistance in breast cancer 
has been attributed to several proteins, the pathway involving the human epidermal 
growth factor receptor (HER) family is a very important one.  The HER family of 
proteins leads to the phosphorylation of a protein kinase b (Akt-a serine threonine 
3
kinase), which in turn phosphorylates many other proteins in the phosphoinositide-3-
kinase (PI-3K) pathway.  Upon phosphorylation of Akt, apoptosis is suppressed [14].  
Over-expression of p-glycoprotein (p-gp) leads to drug efflux and decreased 
intracellular drug accumulation in cells [4, 6, 15, 16].    P-gp is an ATP-dependent 
membrane efflux pump that maintains intracellular drug concentration below the needed 
cytotoxic levels [6].  Several factors, such as oncogene transfection, cell 
differentiation/proliferation and upregulation of heat shock proteins, can alter the cellular 
expression of P-gp [6].  P-gp is the most studied and best characterized drug resistance 
mechanism, but is highly unlikely to account for all the drug resistance seen in many 
tumors [15, 17].  P-gp is encoded by a group of related genes called mdr, of which there 
are two types (mdr1 and mdr2) in the human genome [6].  Mdr 1 has been shown to 
impart drug resistance in human tumor cells [6].  P-gp is found mainly in cells lining the 
luminal space in normal tissues [6].  Its localization denotes its role as an efflux pump 
with a protective role against cytotoxins [6].  P-gp and the level of expression of the mdr1 
gene have been suggested to be one of the prognostic factors in patients with different 
malignancies [6].  Topoisomerase II, which will be discussed later, has been proposed as 
a mechanism for non-pgp mediated drug resistance in many cell models [15].  Drugs such 
as verapamil, a calmodulin antagonist and calcium channel blocker, have been shown to 
restore the sensitivity in vitro of resistant cells to cytotoxic drugs that function by 
blocking the function of p-gp [6].
P53 gene is a nuclear gene involved in the normal proliferation of cells.  It is 
expressed in very high levels in tumor derived cell lines [18].  Mutations of p53 have 
been identified in a number of breast tumors [19, 20]. 
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Altered expression levels of other proteins such as type 1 topoisomerase, 
glutathione-related enzymes and protein kinase C (PKC) have also been observed in drug 
resistant cells [15, 21].  For example, tissue transglutaminase (tTGase), a protein cross-
linking enzyme, which also facilitates apoptosis, has been shown to be overexpressed in 
the MCF-7 cells selected for resistance to doxorubicin [15].   
Drug resistance is a major obstacle in the treatment of any cancers.  Cellular 
mechanisms that contribute to MDR include increased efflux (ATP-dependent efflux 
pumps), decreased influx, activation of DNA repair, blocked apoptosis (example: 
decreased ceramide levels) and activation of detoxifying systems by the glutathione 
system (cytochrome p450) [6, 11, 15, 22, 23].  However, several studies have shown that 
acquired drug-resistant phenotypes in vitro express a vast variety of alterations, including 
protein kinase C overexpression, loss of epithelial markers, increased accumulation of 
p53 protein, altered expression of growth factors or changes in growth rate [11].  A study 
by Vickers et al showed that the overexpression of p-gp and doxorubicin resistance were 
accompanied by a loss of estrogen receptor and increased expression of epidermal growth 
factor (EGF) [24].  Loss of estrogen receptor and increased levels of EGF receptor 
expression have been correlated with poor prognosis in patients with breast cancer [25-
29].  The recurrent alterations in growth factors suggests that they play an important role 
in drug resistance, although the precise mechanism is unknown [22, 30].  
The MCF-7 cell line used in this experiment was originally obtained from a 
pleural effusion and is epithelial-like in morphology [31].  The drug-resistant cell lines 
used in our laboratory include doxorubicin-MCF7, etoposide-MCF7, melphalan-MCF7 
and mitoxantrone-MCF7. 
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Doxorubicin (adriamycin) is one of the most effective therapeutic drugs available 
for the treatment of solid tumors including breast cancer [15].    Doxorubicin is an 
inhibitor of reverse transcriptase and RNA polymerase.  As an RNA polymerase 
inhibitor, it binds to DNA and prevents transcription, thereby preventing cell growth.  In 
addition to being an RNA polymerase and reverse transcriptase inhibitor, it is also an 
immunosuppressive agent, and a DNA topoisomerase II (DNA gyrase) inhibitor [2, 4, 32, 
33].  Topoisomerase II is the main target of doxorubicin [33].  Doxorubicin generates free 
radicals that cause strand breaks in DNA [2, 33, 34].  One of the factors contributing to 
resistance to doxorubicin has been shown to be decreased accumulation of drug [35].  
Other studies have attributed doxorubicin resistance to alterations in topoisomerase II 
activity, increased inactivation of radicals by increases in gluthathione-dependent 
enzymes [2, 6], increases in drug efflux and increased p-gp expression [2, 4].  The 
effectiveness of doxorubicin is limited by both intrinsic drug resistance and the 
development of drug resistant tumor subpopulations [15].  This is the main reason why it 
is important to analyze proteins involved in doxorubicins’ drug resistance.
Etoposide (Vp16) complexes with DNA and topoisomerase II to enhance single 
and double strand cleavage and reversibly inhibit relegation [2, 33, 34, 36].  Etoposide 
arrests the cell in both the synthesis and growth phases of the cell cycle, thereby inducing 
apoptosis [2, 34].  Resistance has been shown to be due to an alteration in the DNA 
topoisomerase II activity [36, 37]. 
 Melphalan forms DNA cross-links that are crucial for cytotoxic effects [2, 38].  
Resistance to melphalan has been shown to be mostly due to reduced drug intake [37] 
and increased DNA cross-linking repair [38].  
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Mitoxantrone is a chemotherapeutic agent similar in structure to doxorubicin [38].  
Its precise mechanism of action is not fully known, however it is most likely associated 
with chromosomal elements, resulting in DNA damage and inhibition of nucleic acid 
synthesis and DNA strand breaks, which in turn result in cell death [38].  Resistance to 
mitoxantrone is reported to be mostly due to drug efflux [39].  
To successfully analyze proteins in cells, fractionation of cellular components is 
preferable, if not a must.  Subcellular fractionation employs differential centrifugation as 
its primary method.  Fractionation of the cell should make it easier to analyze proteins, 
which contribute to drug resistance.  Proteins in cells have a wide range of properties and 
abundance levels.  This causes a great deal of complexity when analyzing whole cell 
extracts.  Reducing this complexity by analyzing protein subsets has improved analysis of 
low abundance proteins and contributed information about the localization of various 
proteins in the cell.   Finally, even proteins isolated in subcellular fractions must be 
further fractionated for successful global analysis.
Many high molecular mass proteins involved in MDR have been identified and 
studied, but only a few low molecular mass proteins have been examined.  It is very 
likely that many more proteins than have been identified are involved in the MDR 
mechanism.  Several methods are available for the separation and identification of large 
proteins, but effective methods are yet to be proven successful for small proteins. In part, 
this is because low molecular mass proteins are not well resolved on 1- and 2-
dimensional gel electrophoresis.  In order to effectively carry out a comparative analysis 
between two cell lines, it will be important to isolate, identify and analyze as many small 
proteins as possible, because these might play an integral role in the mechanism of drug 
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resistance.  The development of new techniques is needed for the analysis of low 
molecular mass proteins.  
  Two-dimensional polyacrylamide gel electrophoresis (2D PAGE) is a protein 
separation technique that is widely used.  Proteins are separated in the first dimension 
according to isoelectric points (PI)/charge, and in the second dimension according to 
molecular weight.  In-gel digestion is used to identify the proteins on the gel.  Each spot 
on a 2D PAGE corresponds to one (or occasionally more) protein(s) due to this method’s 
high resolution. A major advantage of this method is that crude extracts can be applied 
directly with high resolution.  The separated proteins can be identified using mass 
spectrometry for microsequencing or peptide finger printing.  This method, however, 
favors the visualization of relatively abundant proteins and requires a relatively large 
amount of sample.  It is also difficult to separate hydrophobic proteins and proteins of 
extreme PI’s on a 2D-gel.    The limitations of 2-D electrophoresis have made it 
necessary to probe for more efficient methods of separating low molecular mass proteins.  
One-dimensional polyacrylamide gel electrophoresis (1D PAGE) is another 
separation method that separates proteins according to size and molecular weight.  Each 
band on a 1D PAGE could contain many proteins, and in-gel digestion and 
microsequencing are usually required to correctly identify proteins.  1D PAGE is a great 
visualization tool to estimate the mass range of proteins in a given mixture.  Using a 
molecular standard as a marker, one can estimate the molecular weights of proteins in the 
sample.  
High performance liquid chromatography is another powerful separation 
technique used in protein biochemistry.  Biological compounds can be separated with 
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good resolution, convenience and sensitivity, given that the sample is soluble in the liquid 
phase.  
Mass Spectrometry is a rapidly evolving area in proteomics.  “A mass 
spectrometer determines the mass of a molecule by measuring its mass per charge ratio 
(m/z)” [40].  Ions are generated by a loss or gain of electrons or protons from a neutral 
species and are then directed to the analyzer where the ions are separated according to 
mass/charge and then detected by a detector [40].  The most common ionization sources 
for proteins are electrospray ionization and matrix-assisted laser desorption/ionization 
(MALDI).  MALDI was used in this experiment due to its excellent sensitivity, suitability 
for peptides, relative tolerance to complex mixtures and soft ionization.  Linear time-of-
flight (TOF) and time-of-flight reflectron analyzers were used in this experiment due to 
their great compatibility with MALDI and fast scanning speed.   Post source decay (PSD) 
is an extension of MALDI/MS that aids in the observation and identification of fragment 
ions from the decay of a precursor ion, taking place after leaving the ion source [41]. 
Mass spectrometry is usually combined with gel electrophoresis, HPLC or other 
separation methods.  Mass spectrometry is also an excellent tool for identifying post-
translational modifications [42-44].
Data from the MALDI spectra can be submitted to protein databases in an effort 
to identify proteins in a sample.  When peptide mass or sequence information is 
submitted to the database, a score and probability are generated for each protein.  The 
probability is based on the observed match between the experimental data set and each 
database query occurring by chance.  The lowest probability results in the best match.  
The significance of the best match depends on the size of the database.  The way that 
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Mascot measures the significance threshold is to see if the probability of an observed 
event occurring by chance is less than 1 in 20 (p<0.05).  Score = -10 log (p), where p is 
the probability of an event occurring by chance.  Therefore, the best match will also have 
the lowest probability, which will result in the highest scores.  
The objective of my research is to evaluate a new method for enrichment of low 
molecular mass proteins, a method that will optimize the identification of low molecular 
mass proteins in the cytosolic fraction of the MCF-7 cell lines.  The cytosol houses the 
cell organelles and is the site of most cellular metabolism.  It contains numerous proteins 
that control cellular mechanism such as signal transduction, glycolysis, intracellular 
receptors and transcription factors [45].  The analysis of cytosolic proteins is therefore 
very important in proteomics.  The method used in my research, acetonitrile precipitation, 
was proposed in a talk by Andrew Alpert from the PolyLC Company who suggested that 
this might be a way of reducing the complexity of fractionation of low from high 
molecular mass proteins.    
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EXPERIMENTAL
MCF-7 Growth and Harvesting
MCF-7 drug susceptible cells were grown and harvested in our lab [46].  This cell 
line was a gift from K.H. Cowan (Eppley Institute, University of Nebraska Medical 
Center, Omaha, NE).  The cells were grown on 150 cm2 flasks (Corning, Inc., Corning, 
NY) in Minimal Essential Medium Eagle (ATCC, Manassas, VA), 5% fetal bovine serum 
(Sigma) and 0.1% penicillin-streptomycin antibiotic solution and 0.25% trypsin-EDTA 
(Sigma).  The cells were maintained at 37°C with 5% carbon dioxide.  Upon confluence, 
the cells were harvested.  To harvest the cells, the cells were washed twice with 25ml 1x 
phosphate buffer saline solution (PBS). Then 5ml of trypsin was added to the washed 
cells and incubated at 37°C for 5 minutes.   Next, 15 ml of media containing serum was 
added to inhibit the protease.  The cells were centrifuged at 500g for 5 minutes.  The cell 
pellet was washed twice with 25 ml of ice-cold 1x PBS and 25 ml of ice- cold 100mM 
NaCl, and centrifuged at 500g in between washes.  
Cytosolic Extraction
The cells were incubated with digitonin extraction buffer [.015% digitonin, 
100mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), 300mM sucrose, 5M NaCl, 
1M MgCl2, 100mM ethylenediaminetetraacedic acid (EDTA), and 100mM 
phenylmethylsulflfonyl fluoride (PMSF)] with the ratio of 3.7 ml per gram of wet cells.  
The cells were centrifuged at 800 g for 15 minutes.  The supernatant was then centrifuged 
at 5000 g for 20 minutes, and the supernatant obtained from this centrifuge was further 
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centrifuged at 90,000 g for 2 hours.  The purified cytosolic extract was stored in 0.5 ml 
aliquots at -80°C.  
Acetonitrile Precipitation
A 1:1 ratio by volume of the purified aqueous cytosolic extract and acetonitrile 
(HPLC grade from Fisher Scientific; Fair Lawn, NJ) was used for the precipitation 
studies.  The cytosolic extract and acetonitrile mixture was placed on ice for 1 hour.  
Next, it was centrifuged (Eppendorf Centrifuge 5415 D) at 5000 revolutions per minute 
(rpm) for 5 minutes.  The supernatant was dried in the SPD Speed Vac RVT 400 
refrigerated vapor trap (Savant Instruments; Holbrook, NY).  The residue was re-
suspended in 0.1% Triflouroacetic acid (TFA).  The acetonitrile precipitation scheme is 
shown in Figure 1. 
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Purified Cytosolic Extract (aqueous)
Add 1:1 by volume acetonitrile
Sit on ice for 1 hour
           Centrifuge
Precipitate Supernatant
Dry
Resuspend w/ 0.1% TFA
Figure 1: Acetonitrile Precipitation Scheme
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Protein Assay
The protein concentration of the cytosolic extract and the supernatant were 
determined using the Bio-Rad Protein Assay (Hercules, CA) dye reagent following the 
manufacturer’s instructions.  The protein concentration was detected using a Beckman
DU530 Life Science UV/Vis Spectrophotometer (Brea, CA).  Absorbance was measured 
at 595nm.   
1-Dimensional SDS gel electrophoresis
The precipitate was rehydrated in loading buffer (2-mercaptoethanol and Laemmli 
Sample Buffer) (Bio-Rad).  Approximately 10 µg of the cytosolic extract, supernatant 
and precipitate were loaded into a well on a Bio-Rad Criterion Precast Gel (4-15%, Tris-
HCl, 1.0 mm, 12 + 2 comb, 45 µL) in a Mini PROTEAN 3 (Bio-Rad) gel box with 
running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS).  The gel separation was run 
for approximately 45 minutes at 200 volts using the Bio-Rad Power Supply Model 
1000/500.  The gel was fixed in 50% methanol, 5% acetic acid and 45% water for 30 
minutes and then re-hydrated with water for 15 minutes.  The gel was further stained with 
Bio-Safe Coomassie (0.025% Coomassie blue G250, 10% acetic acid) (Bio-Rad) for 1 




Prior to analyzing the supernatant on the mass spectrometry, the supernatant from 
the acetonitrile precipitation was desalted.  A Zip tipC4 (Millipore Corporation: Belerica, 
Massachusetts) was used following the manufacturer’s instructions.
Mass Spectrometry
In order to further test the reliability of the acetonitrile precipitation method, the 
desalted supernatant sample was analyzed using the MALDI Kratos PC Axima-CFR Plus 
(Shimadzu Kratos, Chestnut Ridge, NY) prior to HPLC separation.  3,5-Dimethoxy-4-
hydroxycinnamic acid was used as the matrix.  A 1:1 ratio of matrix and sample was 
loaded on the sample plate and analyzed at a laser power of 65 in the linear mode.   
High Performance Liquid Chromatography (HPLC)
Instrumentation and Chemicals:
A Shimadzu (Columbia, MD) HPLC system, was used with UV detection.  
Acetonitrile was HPLC grade from Fisher Scientific (Fair Lawn, NJ) and trifluoroacetic 
acid (TFA) was from Aldrich Chemicals (Milwaukee, WI). 
Reversed-Phase Chromatography
Separations of the supernatant post acetonitrile precipitation were performed on a 
Shimadzu HRC-ODS 4.6mm x 150mm column.  The mobile phase components are (A) 
0.1% TFA in HPLC grade water and (B) acetonitrile in 0.1% TFA.  Proteins were 
detected at 254 nm at a flow rate of 1 mL/min.  The fractions were collected manually
and dried in the SPD Speed Vac RVT 400 refrigerated vapor trap.  0.1% TFA was added 
to the dried sample, which was analyzed by MALDI-TOF MS in the linear mode.  
Fractions containing protein peaks were digested.
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Tryptic digestion
Some of the HPLC fractions were selected for digestion.  The fractions were dried 
and resuspended in 50mM ammonium bicarbonate (CH203.H3N).  A 1:1 ratio of 
supernatant and trypsin (trypsin was dissolved in 50mM ammonium bicarbonate 
(CH203.H3N)).  The mixture was incubated overnight at 37°C and the reaction was 
stopped with 0.1% TFA.   The peptide mixture was then analyzed by MALDI-TOF MS 
in the reflectron mode using α-cyano-4-hydroxycinnamic acid as matrix.  Post source 
decay (PSD) measurements were performed on some of the fractions. 
Database searches
 The MALDI spectra were analyzed using Mascot 
(http://www.matrixscience.com) as shown in figure 2.  Peptide mass fingerprint was 
performed using the SwissProt database, allowing up to 1 missed cleavage and a peptide 
mass tolerance of ± 1 Dalton.  The PSD analysis was performed using the Mascot 
sequence query and the SwissProt database, allowing up to 1 missed cleavage, a peptide 
tolerance of ± 2 Dalton and an MS/MS tolerance of ± 2 Dalton.  
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                                            Cytosolic extract (aqueous)           1-D gel
Acetonitrile precipitation 
Precipitate      Supernatant
1-D gel               Dry
                                                                      Resuspend in 0.1% TFA
Desalt
1-D gel      HPLC
MALDI
Dry fractions
         Resuspend in 0.1% TFA
MALDI
Tryptic digest of selected protein peaks
          MALDI
Analyze using protein database (Mascot)




The concentration of the purified cytosolic extract was determined to be 1.7 
mg/ml, while that of the supernatant was determined as 0.08 mg/ml.  
1-Dimensional Gel Electrophoresis
The 1-dimensional gel separations of the purified cytosolic extract, precipitate and 
supernatant were imaged.  Gel patterns from two experiments are shown in figures 3 and 
4.  
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The cytosolic fraction contains all the proteins in the extract.  The bands from the 
precipitate reveal the same large proteins as the cytosolic fraction.  The supernatant can 
be seen to contain mainly low molecular mass proteins.  A second gel separation was run 
using a second aliquot from the original cytosol extract and the same molecular weight 
standard, and is shown in figure 4.  In both cases, a differential distribution of proteins 
can be seen between the precipitate and the supernatant, with lower molecular weight 
proteins being enriched in the supernatant.    
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The MALDI spectrum of the desalted supernatant after the acetonitrile 
precipitation is shown in figure 5.  This shows an abundance of low mass proteins.  The 
supernatant is enriched for low molecular weight proteins as expected.  HPLC was 
performed on the supernatant to purify and separate the low molecular weight proteins.  















































Figure 5: MALDI-TOF MS spectrum of supernatant of the acetonitrile precipitation.
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The HPLC chromatogram of the supernatant is shown in figure 6.  The numbered peaks 
were selected for tryptic digestion and further analysis by peptide mass fingerprinting and 
microsequencing.  
Figure 6: HPLC chromatogram of the supernatant of the acetonitrile precipitation.
A MALDI spectrum was obtained for each fraction collected (figures 7, 10 and 
13).    Tryptic digestion was performed for fractions 9, 14 and 15.  These fractions were 
selected for digestion because they showed protein peaks on the MALDI spectra.   The 
MALDI spectra of the digested peaks are shown in figures 8, 11 and 14.  PSD was 
performed on the most abundant peptide of the tryptic digestion from each fraction.  The 
PSD-MALDI-TOF spectra are shown in figures 9, 12 and 15.
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Figure 7:  MALDI-TOF MS spectrum of HPLC fraction 9
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Figure 8:  MALDI-TOF MS spectrum of digested HPLC fraction 9
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Figure 9:  MALDI-TOF-PSD spectrum of HPLC fraction 9.
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Figure 10:  MALDI-TOF MS spectrum of HPLC fraction 14
27










































Figure 11:  MALDI-TOF MS spectrum of digested HPLC fraction 14
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Figure 12:  MALDI-TOF-PSD spectrum of HPLC fraction 14
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Figure 13:  MALDI-TOF MS spectrum of HPLC fraction 15
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Figure 14:  MALDI-TOF MS spectrum of digested HPLC fraction 15
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Figure 15:  MALDI-TOF-PSD spectrum of HPLC fraction 15
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Microsequence analysis of the PSD fragment ions was performed using Mascot and the 
SwissProt database.  One protein each was identified for fractions 14 and 15.  Table 1 
shows the identified proteins, their molecular weights and scores.
Fraction 
Number




trans isomerase A 
(PPIase)
P05092 17870 126
15 Profilin 1 P07737 14914 59
Table 1: PSD Mascot results.  Scores ≥ 53 are significant.
PSD of fraction 9 resulted in proteins with no significant scores.
Sequence of PPIase
        10         20         30         40         50         60 
         |          |          |          |          |          | 
VNPTVFFDIA VDGEPLGRVS FELFADKVPK TAENFRALST GEKGFGYKGS CFHRIIPGFM 
        70         80         90        100        110        120 
     |          |          |          |          |          | 
CQGGDFTRHN GTGGKSIYGE KFEDENFILK HTGPGILSMA NAGPNTNGSQ FFICTAKTEW 
       130        140        150        160 
         |          |          |          | 
LDGKHVVFGK VKEGMNIVEA MERFGSRNGK TSKKITIADC GQLE 
Sequence of Profilin 1
        10         20         30         40         50         60 
         |          |          |          |          |          | 
AGWNAYIDNL MADGTCQDAA IVGYKDSPSV WAAVPGKTFV NITPAEVGVL VGKDRSSFYV 
        70         80         90        100        110        120 
         |          |          |          |          |          | 
NGLTLGGQKC SVIRDSLLQD GEFSMDLRTK STGGAPTFNV TVTKTDKTLV LLMGKEGVHG 
       130 
         | 
GLINKKCYEM ASHLRRSQY 




One dimensional gel electrophoresis is a good way of visualizing proteins in a 
sample, in addition to providing approximate molecular weights for these proteins.  The 
protein mixtures loaded on the gels in figures 3 and 4 show that the proteins migrate
according to molecular weight and provide an approximation for the proteins’ molecular 
weights.
  The hypothesis for this experiment is that heavier proteins come out of solution 
more readily than the lighter proteins, when exposed to acetonitrile and a lower 
temperature.  The insoluble proteins are centrifuged into the precipitate.  After 
centrifugation of the proteins, less soluble heavy proteins should be found in the 
precipitate, while the more soluble lighter ones remain in the supernatant.  The 
experimental results do not show a clear separation of small from high molecular mass 
proteins.  The proteins in the purified cytosolic extract range from approximately 6.8 –
206.9 kDa.  This represents a wide range of proteins with regards to size.  The proteins in 
the precipitated fraction are enriched for the high molecular mass proteins, and definitely 
contain the same high mass proteins as the protein sample prior to the acetonitrile 
precipitation.  The 1-D gels and the MALDI mass spectrum show an abundance of low 
molecular mass proteins in the supernatant fraction.  
Using the Mascot protein search engine and the SwissProt database, some 
proteins with significant scores were identified based on peptide mass maps.  Most of 
these have masses below 30 kDa.  These were discarded as potential proteins due to the 
complex mixture of the supernatant, and the incomplete separation by HPLC as shown in 
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figures 7, 10 and 13.  The MALDI-TOF MS spectra in these figures indicate an 
abundance of several proteins, which should not be the case, had there been a complete 
HPLC separation and purification.  Therefore it is unreliable to identify proteins in these 
fractions by peptide mass fingerprinting.  Two proteins with significant scores were 
identified based on microsequencing, with masses below 20 kDa.  The proteins identified 
are Peptidyl-prolyl cis- trans isomerase A (PPIase) from fraction 14 and Profilin 1 from 
fraction 15.  Profilin 1 has also been identified in the cytosolic extract of the drug 
susceptible MCF-7 cell line using 2-D gel in our laboratory.  Profilin 1 is a ubiquitous 
protein that binds to actin and affects the structure of the cytoskeleton.  It has different 
effects on actin at high and low concentrations.  At high concentrations, it prevents the 
polymerization of actin, while it enhances the polymerization of actin at low 
concentrations [47].  PPIase is an enzyme that catalyzes the isomerization of proline 
residues in proteins [47].
The main goal of this experiment was to provide a means of separating small from 
high molecular mass proteins, so that these proteins can be analyzed to see if they play a 
role in drug resistance.  The supernatant fraction is clearly enriched in small molecular 
mass proteins, which are reduced in the precipitated fraction.  Although there is no cut-
off for low and high molecular weight proteins, this method has proved to be successful 
in enriching for small molecular mass proteins.  Although there is not a complete 
separation, there is a reproducible delineation of the small from large molecular mass 
proteins.  Therefore this method can be used to enrich for small proteins, which can be 
further analyzed by HPLC, in-gel digestion, mass spectrometry and database searching.  
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Conclusion
Although acetonitrile precipitation did not result in complete protein separation, 
there is obviously enrichment for small molecular mass proteins in the supernatant.  
This method offers a way of preparing/separating complex mixtures of proteins for 
easier handling.  This method can be used prior to HPLC or 1- and 2-dimensional gel 
electrophoresis, in an effort to effectively identify small proteins in complex mixtures 
such as the cytosol extract studied here.  
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